Session: SAT 723-745-Lipids: Fatty Liver Disease & Lipodystrophies
Poster Board SAT-740
Objective: To investigate the association between serum TSH, anti-thyroid peroxidase, and 25 (OH) D in an obese population
Design and patients: Prospectively collected database of ‘Obesity Polyclinic’ were used. Subjects with body-mass index (BMI) ≥ 30 kg/m2, having no exclusion criteria (glucocorticoid treatment, Cushing syndrome, thyroidectomy, thyrotoxicosis, photosensitivity, pituitary insuffiency, uncontrolled diabetes mellitus: insulin or more than two oral antidiabetics requirement, HbA1c ≥9%, fasting plasma glucose ≥ 180 mg/dL, chronic kidney disease, chronic liver disease, immobility) have been evaluated for metabolic syndrome criteria (Alberti et al., 2009) and serum TSH, anti-tpo, 25 (OH) D, HOMA-IR.
Results: Of whom criteria were available (n= 548, male=64, 43 years old), 277 were diagnosed with metabolic syndrome (Met-S (+)). Met-S (+) patients had higher BMI (36.4 vs 32.3 kg/m2, p<0.001), Percentage of body fat=PBF (46.6 vs 44.1%, p=0.004), similar TSH (2.1 vs 2.2 mIU/L, p=0.759), 25 (OH) D (13.2 vs 12.6 ng/mL, p= 0.409), anti-tpo (12 vs 13 IU/mL, p=0.483), compared with Met-S (-) subjects. When overall the study population analysed for the number of Met-S criteria (from 1 to 5); BMI, PBF, HOMA-IR, ALT, AST, creatinine levels increased with increased number of metabolic disturbances, while TSH, anti-tpo or 25 (OH)D did not differ between subgroups. Similarly, when serum TSH, anti-tpo, and 25 (OH) D levels were analysed in tertiles (Q1-Q3) in order to compare the number of met-S criteria, FPG, TG, HDL-C, BMI, PBF; the only correlation was the increase in BMI and PBF with the decrease in 25 (OH) D levels.
Conclusion: In obese subjects, although decreased 25 (OH) D levels are related to the degree of obesity, serum 25 (OH) D levels themselves do not seem to be associated with metabolic syndrome components. Similarly, neither serum TSH nor anti-tpo levels correlate with metabolic syndrome components in obese subjects.
Nothing to Disclose: KA, YM, RC, MFA, SK
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters